• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Du Pont's Neurolite approved by FDA

Article

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.